{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:13:18Z","timestamp":1767373998163,"version":"3.37.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The 2016 IDSA guideline recommends a treatment duration of at least 7 days for hospital-acquired (HAP)\/ventilator-associated pneumonia (VAP). The limited literature has demonstrated higher rates of recurrence for non-glucose fermenting gram-negative bacilli with short course therapy, raising the concern of optimal treatment duration for these pathogens. Therefore, we aimed to compare the outcomes for patients receiving shorter therapy treatment (\u2264\u20098 days) versus longer regimen (&gt;\u20098 days) for the treatment of multidrug resistant (MDR) <jats:italic>Pseudomonas<\/jats:italic> pneumonia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A single-center, retrospective cohort study was conducted to evaluate adult patients receiving an antimicrobial regimen with activity against MDR <jats:italic>Pseudomonas aeruginosa<\/jats:italic> in respiratory culture between 2017 and 2020 for a minimum of 6 consecutive days. Exclusion criteria were inmates, those with polymicrobial pneumonia, community-acquired pneumonia, and infections requiring prolonged antibiotic therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 427 patients with MDR <jats:italic>P. aeruginosa<\/jats:italic> respiratory isolates, 85 patients were included. Baseline characteristics were similar among groups with a median age of 65.5 years and median APACHE 2 score of 20. Roughly 75% had ventilator-associated pneumonia. Compared to those who received\u2009\u2264\u20098 days of therapy, no difference was seen for clinical success in patients treated for more than 8 days (80% vs. 65.5%, <jats:italic>p<\/jats:italic>\u2009=\u20090.16). The number of 30-day and 90-day in-hospital mortality, 30-days relapse, and other secondary outcomes did not significantly differ among the treatment groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Prolonging treatment duration beyond 8 days did not improve patient outcomes for MDR <jats:italic>P. aeruginosa<\/jats:italic> HAP\/VAP.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-024-09600-w","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T07:02:44Z","timestamp":1725346964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Duration of antibiotic therapy for multidrug resistant Pseudomonas aeruginosa pneumonia: is shorter truly better?"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8827-3016","authenticated-orcid":false,"given":"Clover N.","family":"Truong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nafeesa","family":"Chin-Beckford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kailynn","family":"DeRonde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilian M.","family":"Abbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossana","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine A.","family":"Vu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"issue":"13","key":"9600_CR1","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","volume":"370","author":"SS Magill","year":"2014","unstructured":"Magill SS, Edwards JR, Bamberg W, et al. Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198\u2013208.","journal-title":"N Engl J Med"},{"key":"9600_CR2","unstructured":"CDC. Threat Report \u2013 Pathogen Page: Multi-drug Resistant Pseudomonas. 2019. Accessed on May 23rd, 2021."},{"issue":"5","key":"9600_CR3","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated Pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of American and the American thoracic society. Clin Inf Dis. 2016;63(5):e61\u2013111.","journal-title":"Clin Inf Dis"},{"key":"9600_CR4","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1001\/jama.290.19.2588","volume":"290","author":"J Chastre","year":"2003","unstructured":"Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290:2588\u201398.","journal-title":"JAMA"},{"key":"9600_CR5","doi-asserted-by":"crossref","unstructured":"Pugh R, Grant C, Cooke RPD et al. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Reviews 2015; 8.","DOI":"10.1002\/14651858.CD007577.pub3"},{"key":"9600_CR6","unstructured":"Hart DE, Gallagher JC, Puzniak LA et al. A multicenter evaluation of ceftolozane\/tazobactam treatment outcomes in immunocompromised patients with multidrug-resistant Pseudomonas aeruginosa infections. OFID 2021; 8(3): ofab089."},{"issue":"3","key":"9600_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/phar.2201","volume":"39","author":"BF Teshome","year":"2019","unstructured":"Teshome BF, Vouri SM, Hampton N, Kollef MH, Micek ST. Duration of exposure to Antipseudomonal \u03b2-Lactam antibiotics in the critically ill and development of New Resistance. Pharmacotherapy. 2019;39(3):261\u201370.","journal-title":"Pharmacotherapy"},{"key":"9600_CR8","doi-asserted-by":"crossref","unstructured":"Bougl\u00e9 A, Tuffet S, Federici L, Leone M, Monsel A, Dessalle T, Amour J, Dahyot-Fizelier C, Barbier F, Luyt CE, Langeron O, Cholley B, Pottecher J, Hissem T, Lefrant JY, Veber B, Legrand M, Demoule A, Kalfon P, Constantin JM, Rousseau A, Simon T, Foucrier A. iDIAPASON Trial Investigators. Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial. Intensive Care Med. 2022;48(7):841\u2013849. doi: 10.1007\/s00134-022-06690-5. Epub 2022 May 13. Erratum in: Intensive Care Med. 2022;: PMID: 35552788.","DOI":"10.1007\/s00134-022-06690-5"},{"issue":"3","key":"9600_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","volume":"18","author":"A Torres","year":"2018","unstructured":"Torres A, Zhong N, Pachl J, et al. Ceftazidime-Avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18(3):285\u201395.","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"9600_CR10","doi-asserted-by":"publisher","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","volume":"73","author":"I Titov","year":"2021","unstructured":"Titov I, Wunderink RG, Roquilly A, et al. A Randomized, Double-blind, Multicenter Trial comparing efficacy and Safety of Imipenem\/Cilastatin\/Relebactam Versus Piperacillin\/Tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 study). Clin Infect Dis. 2021;73(11):e4539\u201348.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"9600_CR11","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","volume":"19","author":"MH Kollef","year":"2019","unstructured":"Kollef MH, Nov\u00e1\u010dek M, Kivistik \u00dc, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2019;19(12):1299\u2013311.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"9600_CR12","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1097\/01.CCM.0000275389.31974.22","volume":"35","author":"J Garnacho-Montero","year":"2007","unstructured":"Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al. Optimal management therapy for P. Aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med. 2007;35(8):1888\u201395.","journal-title":"Crit Care Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09600-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-09600-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09600-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T19:03:50Z","timestamp":1725390230000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-09600-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9600"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-09600-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2024,9,3]]},"assertion":[{"value":"14 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The University of Miami Institutional Review Board (IRB) and Jackson Health System Clinical Research Review Committee (CRRC) approved the study and granted a waiver of informed consent. All methods were carried out in accordance with relevant guidelines and regulations. Data collected was kept and treated as confidential at all times.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"911"}}